Aurobindo gets USFDA nod to market new drug

New Delhi: Aurobindo Pharma on Thursday said its subsidiary has received approval from the US health regulator to market a generic medication to treat asthma in children.

Eugia Pharma Specialities, a wholly-owned subsidiary of the company, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Budesonide Inhalation Suspension, the Hyderabad-based drug firm said in a regulatory filing. The company’s product is therapeutically equivalent to Astrazeneca Pharmaceuticals LP’s Pulmicort Repsules Inhalation Suspension, it added.